ESMO 2018: Athenex Presented Encouraging Clinical Trial Efficacy and Safety Results of Oraxol in the Treatment of Metastatic Breast Cancer
October 22, 2018 07:00 ET
|
Athenex, Inc.
BUFFALO, N.Y., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Athenex (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the...
Athenex to Present Positive Data of Oraxol Clinical Trial in Breast Cancer at the ESMO 2018 Congress
October 16, 2018 08:07 ET
|
Athenex, Inc.
BUFFALO, N.Y., Oct. 16, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for...
Athenex and Xiangxue Life Sciences Announce Preliminary Results of Patients Receiving T-Cell Receptor Affinity Enhancing Specific T-Cell Therapy (TAEST) Showed Encouraging Positive Clinical Signals
October 15, 2018 07:00 ET
|
Athenex, Inc.
BUFFALO, N.Y., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for...
Athenex與合作夥伴Hanmi Pharmaceutical宣布調整合作項目的策略
September 19, 2018 06:05 ET
|
Athenex, Inc.
紐約州水牛城, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc.（納斯達克︰ATNX）是一家致力於研發、發展以及將治療癌症及相關疾病新型療法商業化的全球生物製藥公司。Athenex與合作夥伴Hanmi Pharmaceutical今日宣布調整合作項目的策略，以進一步探索和拓展這些項目成為全球業務。 根據有關調整，Athenex與Hanmi...
Athenex and its Collaborative Partner, Hanmi Pharmaceutical, Announce Strategic Realignment of their Joint Projects
September 12, 2018 08:00 ET
|
Athenex, Inc.
BUFFALO, N.Y., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for...
Athenex宣布公司藥物安全監督委員會在分析第二次中期臨床試驗的結果後，極力推薦繼續進行Oraxol第 III期臨床試驗計劃
September 05, 2018 16:21 ET
|
Athenex, Inc.
紐約州水牛城, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc.（納斯達克：ATNX）是一家致力於研發、發展以及將治療癌症及相關疾病新型療法商業化的全球生物製藥公司。該公司宣布獨立藥物安全監測委員會（DSMB）已按計劃對轉移性乳腺癌新藥Oraxol 001...
Athenex Announces Positive Recommendation by the Drug Safety Monitoring Board Upon the Second Interim Analysis and to Continue the Oraxol Phase III Program
September 05, 2018 07:00 ET
|
Athenex, Inc.
BUFFALO, N.Y., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for...
Athenex 晉升Randoll Sze （施天揚先生）為公司財務總監
August 21, 2018 14:11 ET
|
Athenex, Inc.
紐約州水牛城, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc.（納斯達克︰ATNX）是一家致力於研發、發展以及將治療癌症及相關疾病新型療法商業化的全球生物製藥公司。Athenex今日宣佈晉升施天揚先生為公司財務總監，向公司行政總裁匯報。 ...
Athenex Appoints Randoll Sze as Chief Financial Officer
August 20, 2018 08:00 ET
|
Athenex, Inc.
BUFFALO, N.Y., Aug. 20, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for...
Athenex, Inc.公佈2018年第二季度業績並提供最新公司資料
August 15, 2018 14:16 ET
|
Athenex, Inc.
第二季度收入增至1,160萬美元，去年同期為460萬美元。 從Perceptive Advisors獲得1億美元的戰略投資 光化性角化病的KX2-391兩項第三期試驗實現重要終點 取得基於T細胞受體工程T細胞（TCR-T）的免疫治療平台和基於代謝的腫瘤學候選藥品雙授權 美国紐約州水牛城, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Athenex,...